Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Emma ZattarinSara ManglavitiGiulia ApollonioTeresa BeninatoLaura MazzeoGiacomo MassaAchille BottiglieriEdoardogregorio GalliAlessandro De TomaMario OcchipintiMarta BrambillaRoberto FerraraMonica GanzinelliClaudia ProtoMarina Chiara GarassinoFilippo de BraudGiuseppe Lo RussoArsela PrelajPublished in: Future oncology (London, England) (2022)
Background: Clinical and laboratory biomarkers in patients with advanced non-small-cell lung cancer (aNSCLC) receiving chemo-immunotherapy (CIT) are still poorly explored. Materials & methods: All consecutive aNSCLC patients who received at least one cycle of first-line CIT were enrolled. The impact of several clinical and laboratory biomarkers on outcomes was evaluated through Cox proportional hazard models. Results: Higher neutrophil-to-lymphocyte ratio was shown to be an independent prognostic biomarker of both worse progression-free survival and worse overall survival. The EPSILoN score was able to divide patients into three different prognostic groups, with a median overall survival of 73.2, 45.6 and 8.6 months for the favorable, intermediate and poor groups, respectively. Conclusion: The neutrophil-to-lymphocyte ratio and EPSILoN score were shown to have a prognostic value in aNSCLC patients treated with CIT.
Keyphrases
- advanced non small cell lung cancer
- free survival
- epidermal growth factor receptor
- photodynamic therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- cancer therapy
- prognostic factors
- combination therapy
- squamous cell carcinoma
- drug delivery
- metabolic syndrome
- patient reported outcomes
- skeletal muscle
- patient reported
- insulin resistance